FOLLICULAR T-CELL LYMPHOMA
Clinical trials for FOLLICULAR T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for FOLLICULAR T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancer: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard treatments for people with certain types of T-cell lymphoma that have come back or not responded to therapy. About 150 adults will be randomly assigned to receive either soquelitinib or a standard single-agent chemo…
Matched conditions: FOLLICULAR T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 03:59 UTC
-
New hope for tough lymphoma: experimental drug ST-001 enters human testing
Disease control Recruiting nowThis early-phase trial tests a new drug called ST-001 in people with T-cell non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to find the safest dose and to watch for side effects. About 46 participants will receive the drug through a…
Matched conditions: FOLLICULAR T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: SciTech Development, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC